Moderna, with FDA nod for RSV vaccine, grows reach beyond the pandemic
Fierce Pharma
MAY 31, 2024
With the FDA nod, Moderna's RSV vaccine becomes the company's second product to secure the FDA's backing.
Fri.May 31, 2024
325 
FDA Approves Moderna RSV Vaccine, an mRNA Alternative to GSK and Pfizer Products
MedCity News
MAY 31, 2024
Moderna’s mResvia is now the third FDA-approved RSV vaccine and the first one based on mRNA technology. It will compete for market share against RSV shots from GSK and Pfizer that won their FDA nods last year. The post FDA Approves Moderna RSV Vaccine, an mRNA Alternative to GSK and Pfizer Products appeared first on MedCity News.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
ASCO: In surprise, J&J's injectable Rybrevant extends lung cancer patients' lives versus intravenous version
Fierce Pharma
MAY 31, 2024
When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. | When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. But to Johnson & Johnson’s surprise, a subcutaneous formulation of its lung cancer med Rybrevant proved to work better than the original infusion.
MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Courtney Fortner, CEO of Navvis
MedCity News
MAY 31, 2024
In this month’s episode, Senior Reporter Katie Adams explored some executive moves and layoffs that recently occurred in the healthcare world. She also interviewed Courtney Fortner, who stepped into the CEO role at population health company Navvis this month. The post MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Courtney Fortner, CEO of Navvis appeared first on MedCity News.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
ASCO: Bristol Myers' confirmatory KRAS data avoid Amgen's flaws but still leave FDA prospects unclear
Fierce Pharma
MAY 31, 2024
After Amgen’s KRAS confirmatory trial results were rejected by the FDA as uninterpretable, Bristol Myers Squibb has divulged details of its rival study. | Bristol Myers Squibb has divulged the details of Krazati's confirmatory trial. While the study doesn't share the same design problems as Amgen's rival KRAS program, it still leaves open questions about Krazati's regulatory outlook.
Novartis cues up filings for remibrutinib in chronic hives
pharmaphorum
MAY 31, 2024
Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long-term data from two phase 3 trials.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
Astellas refiles CLDN 18.2 cancer drug after FDA knockback
pharmaphorum
MAY 31, 2024
The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it down earlier this year.
Fierce Pharma Asia—Takeda plots US layoffs; AZ, Daiichi suffer trial setback; Asahi Kasei strikes buyout deal
Fierce Pharma
MAY 31, 2024
Takeda is planning more than 600 layoffs in Massachusetts. AstraZeneca and Daiichi Sankyo's Dato-DXd failed to show an overall survival benefit in a lung cancer study. | Takeda is planning more than 600 layoffs in Massachusetts. AstraZeneca and Daiichi Sankyo's Dato-DXd failed to prove an overall survival benefit in a lung cancer study. Japan's Asahi Kasei is moving to buy rare disease drugmaker Calliditas for about $1 billion.
Gilead’s Trodelvy woes rise with failed bladder cancer trial
pharmaphorum
MAY 31, 2024
Gilead's TROP2 ADC Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma.
Good news in Europe, bad news in US for Sanofi and Regeneron's COPD bid for Dupixent
Fierce Pharma
MAY 31, 2024
A highly anticipated decision on Sanofi and Regeneron’s Dupixent to become the first biologic to treat chronic obstructive pulmonary disorder (COPD) is on hold in the United States but is speeding | A highly anticipated decision on Sanofi and Regeneron’s Dupixent to become the first biologic to treat chronic obstructive pulmonary disorder (COPD) is on hold in the United States but is speeding along in Europe.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Talkspace, Labcorp’s Ovia Health Launch Digital Women’s Health Coalition
MedCity News
MAY 31, 2024
Talkspace and Ovia Health by Labcorp introduced the Women’s Health Coalition for Digital Solutions. Other founding member companies of the coalition include Conceive, Evernow, FitOn, Nurx, Cove and Nutrium. The post Talkspace, Labcorp’s Ovia Health Launch Digital Women’s Health Coalition appeared first on MedCity News.
FDA grants RMAT status for BlueRock’s Parkinson’s therapy
Pharmaceutical Technology
MAY 31, 2024
The US FDA has granted RMAT designation for BlueRock Therapeutics' cell therapy, bemdaneprocel (BRT-DA01), for Parkinson's disease.
Experiencing BCBA Burnout? Why It Happens and Tips to Combat It
MedCity News
MAY 31, 2024
What contributes to the stress and what BCBA employers can do to alleviate it The post Experiencing BCBA Burnout? Why It Happens and Tips to Combat It appeared first on MedCity News.
Dupixent nears EU approval for COPD, as FDA delays
pharmaphorum
MAY 31, 2024
Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive pulmonary disease (COPD). The CHMP’s positive opinion sets up Dupixent (dupilumab) to become the first biologic therapy for COPD in the EU and the first new treatment approach for the disease in over a decade.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharma Pulse 5/31/24: Gen Z’s Passion for Skincare Falls Short on Sun Protection, A Long, But Promising Road Ahead in Clinical Trials & more
Pharmaceutical Commerce
MAY 31, 2024
The latest news for pharma industry insiders.
Work Friction: The Sleeper Crisis Plaguing Healthcare Contact Centers
MedCity News
MAY 31, 2024
How work friction takes shape, how it costs organizations, and how leaders can uncover long-term solutions The post Work Friction: The Sleeper Crisis Plaguing Healthcare Contact Centers appeared first on MedCity News.
NHS platform announced to accelerate personalised cancer vaccine clinical trials
PharmaTimes
MAY 31, 2024
The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines
Gilead Sciences ADC Flunks Its Confirmatory Test in Advanced Bladder Cancer
MedCity News
MAY 31, 2024
Gilead Sciences reported Trodelvy’s Phase 3 test in metastatic urothelial cancer fell short of showing a statistically significant benefit on the overall survival main goal. The antibody drug conjugate had received accelerated FDA approval for this type of cancer in 2021. The post Gilead Sciences ADC Flunks Its Confirmatory Test in Advanced Bladder Cancer appeared first on MedCity News.
The Crick announces new partnerships with SMEs and MRC for research
PharmaTimes
MAY 31, 2024
The projects will focus on a range of research areas, including Down’s syndrome and ALS
Oligonucleotide ALS therapy approved in EU
European Pharmaceutical Review
MAY 31, 2024
The first treatment approved in the EU to target a genetic cause of amyotrophic lateral sclerosis (ALS), has been authorised by the European Commission (EC). QALSODY ® (tofersen) is indicated for adults with ALS associated with a mutation in the superoxide dismutase 1 gene ( SOD1 -ALS). The treatment is an antisense oligonucleotide (ASO) designed to bind to SOD1 mRNA to reduce SOD1 protein production, Biogen shared.
Healthcare Moves: A Monthly Summary of Hires and Layoffs
MedCity News
MAY 31, 2024
Here is a selection of recent executive hires, promotions, retirements and layoffs occurring across the healthcare industry. The post Healthcare Moves: A Monthly Summary of Hires and Layoffs appeared first on MedCity News.
9 Preventive Healthcare Marketing Strategies
Healthcare Success
MAY 31, 2024
Marketing the importance of preventive healthcare services is challenging, costly, and often conflicts with consumer behavior. Despite these hurdles, the urgency to promote prevention has never been greater. Why? The growing number of people diagnosed with preventable chronic diseases each year is staggering (think cancer cases resulting from smoking and diabetes and heart disease cases resulting from obesity).
Increase Revenue With Better, Faster Sales Onboarding
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
European Commission approves Biogen’s QALSODY for ALS treatment
Pharmaceutical Technology
MAY 31, 2024
The EC has approved Biogen's QALSODY to treat adults with amyotrophic lateral sclerosis (ALS) linked to SOD1-ALS mutation.
Regeneron Global Program Head of Linvoseltamab Discusses the Potential for Linvoseltamab to Become a Frontline Treatment for Multiple Myeloma
PharmExec
MAY 31, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Karen Rodriguez-Lorenc, Global Program Head of Linvoseltamab, Regeneron talks about the possibility of linvoseltamab becoming a frontline treatment for multiple myeloma (MM) as well as the company's VelociSuite technology.
Sterling Pharma Solutions to Invest $3 Million in Germantown, WI Plant
Pharmaceutical Commerce
MAY 31, 2024
Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.
Virtual Therapeutics, Akili Interactive Strike Definitive Merger Agreement Seeking to Improve Mental Health Through Immersive Video Games
PharmExec
MAY 31, 2024
Under terms of the deal, Akili will become a wholly owned subsidiary of Virtual Therapeutics, with Akili shareholders receiving $0.4340 per share of common stock in cash.
Understanding the Impact of the Veradigm Network on Value-Based Healthcare Delivery
Pharmaceutical Commerce
MAY 31, 2024
Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.
Scemblix Shows Improved Major Molecular Response Treating Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
PharmExec
MAY 31, 2024
Results of a Phase III trial indicated that Scemblix was more effective than standard-of-care tyrosine kinase inhibitors in treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Tips to Increase New Patient Revenue
Penrod
MAY 31, 2024
1. Personalize Collection Strategies Looking at your historical data can help you create a compelling collection plan for specific patients. Another invaluable tool is the data from a financial clearing house. It’ll help you identify the likelihood of a patient paying and those that might not. You can use this information to determine the best course of action, including decisions to send a patient’s account to a professional collection agency.
Sterling Invests in Expansion of Integrated ADC Services
PharmaTech
MAY 31, 2024
Sterling is strengthening its development and manufacturing services for ADCs with a dedicated GMP suite at its Wisconsin facility.
Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Let's personalize your content